Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Marc Bonaca to Peripheral Arterial Disease

This is a "connection" page, showing publications Marc Bonaca has written about Peripheral Arterial Disease.

 
Connection Strength
  
 
 
31.253
  
  1. Bonaca MP, Catarig AM, Houlind K, Ludvik B, Nordanstig J, Ramesh CK, Rasouli N, Sourij H, Videmark A, Verma S. Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial. Lancet. 2025 05 03; 405(10489):1580-1593.
    View in: PubMed
    Score: 0.591
  2. Bonaca MP, Catarig AM, Hansen Y, Houlind K, Ramesh CK, Ludvik B, Nordanstig J, Rasouli N, Sourij H, Verma S. Design and baseline characteristics of the STRIDE trial: evaluating semaglutide in people with symptomatic peripheral artery disease and type 2 diabetes. Eur Heart J Cardiovasc Pharmacother. 2025 Jan 11; 10(8):728-737.
    View in: PubMed
    Score: 0.582
  3. Lakkireddy D, Angiolillo DJ, Charlton-Ouw K, Jefferson B, Peeran S, Bisharat M, Ortega-Paz L, Harxhi A, Kaul S, Michaud E, Juan S, Woods B, Damaraju CV, Fontana G, Bonaca MP. Rationale and Design of a Study to Assess the Engagement and Usefulness of the Care4Today Connect Digital Health Application for Disease Management in Coronary Artery Disease and Peripheral Artery Disease (iPACE-CVD Study). Clin Cardiol. 2024 Dec; 47(12):e70039.
    View in: PubMed
    Score: 0.578
  4. Bonaca MP, Barnes GD, Bauersachs R, Bessada Y, Conte MS, Dua A, Hess CN, Serhal M, Mena-Hurtado C, Weitz JI, Beckman JA. Antithrombotic Strategies for Patients With Peripheral Artery Disease: JACC Scientific Statement. J Am Coll Cardiol. 2024 Sep 03; 84(10):936-952.
    View in: PubMed
    Score: 0.568
  5. Canonico ME, Low Wang CC, Hsia J, Debus ES, Nehler MR, Patel MR, Anand SS, Ycas J, Capell WH, Muehlhofer E, Haskell LP, Berkowitz SD, Bauersachs R, Bonaca MP. Low-Dose Rivaroxaban Plus Aspirin in?Fragile Patients After Lower Extremity?Revascularization. J Am Coll Cardiol. 2024 Aug 27; 84(9):801-811.
    View in: PubMed
    Score: 0.567
  6. Canonico ME, Hess CN, Secemsky EA, Bonaca MP. Antithrombotic Therapy in Patients Undergoing Peripheral Artery Interventions. Interv Cardiol Clin. 2024 Oct; 13(4):553-559.
    View in: PubMed
    Score: 0.564
  7. Hess CN, Daffron A, Nehler MR, Morrison JT, Buchanan CE, Szarek M, Anderson VE, Cannon CP, Hsia J, Saseen JJ, Bonaca MP. Randomized Trial of a Vascular Care Team vs Education for Patients With Peripheral Artery Disease. J Am Coll Cardiol. 2024 Jun 25; 83(25):2658-2670.
    View in: PubMed
    Score: 0.560
  8. Bonaca MP, Hamburg NM, Creager MA. Stepping Into the Future of Care for Patients With Peripheral Artery Disease. Circulation. 2024 Jun 11; 149(24):1862-1864.
    View in: PubMed
    Score: 0.556
  9. Morrison JT, Canonico ME, Anand SS, Patel MR, Debus ES, Nehler MR, Hess CN, Hsia J, Capell WH, Muehlhofer E, Haskell LP, Berkowitz SD, Bauersachs RM, Bonaca MP. Low-Dose Rivaroxaban Plus Aspirin in Patients With Peripheral Artery Disease Undergoing Lower Extremity Revascularization With and Without Concomitant Coronary Artery Disease: Insights From VOYAGER PAD. Circulation. 2024 May 07; 149(19):1536-1539.
    View in: PubMed
    Score: 0.555
  10. Canonico ME, Hess CN, Rogers RK, Bonaca MP. Medical Therapy for Peripheral Artery Disease. Curr Cardiol Rep. 2024 Jun; 26(6):651-659.
    View in: PubMed
    Score: 0.555
  11. Yuan Z, Levitan B, Deng H, Szarek M, Bauersachs RM, Berkowitz SD, Haskell L, Barnathan ES, Bonaca MP. Quantitative Benefit-Risk Evaluation of Rivaroxaban in Patients After Peripheral Arterial Revascularization: The VOYAGER PAD Trial. J Am Heart Assoc. 2024 Apr 16; 13(8):e032782.
    View in: PubMed
    Score: 0.551
  12. Rogers RK, Herold J, Govsyeyev N, Iezzi R, Morrison J, Hogan SE, Nehler M, Bricker R, Andring B, Bergmark B, Cavender M, Malgor E, Jacobs D, Young MN, Capell W, Ycas JW, Anand SS, Berkowitz SD, Debus ES, Haskell LP, Muehlhofer E, Patel MR, Hess CN, Bauersachs RM, Anderson V, Bonaca MP. Methods, design, and initial results of an angiographic core lab from VOYAGER-PAD. Vasc Med. 2024 04; 29(2):143-152.
    View in: PubMed
    Score: 0.550
  13. McDermott MM, Ho KJ, Alabi O, Criqui MH, Goodney P, Hamburg N, McNeal DM, Pollak A, Smolderen KG, Bonaca M. Disparities in Diagnosis, Treatment, and?Outcomes of Peripheral Artery?Disease: JACC Scientific Statement. J Am Coll Cardiol. 2023 12 12; 82(24):2312-2328.
    View in: PubMed
    Score: 0.540
  14. Canonico ME, Hsia J, Hess CN, Bonaca MP. Sex differences in guideline-directed medical therapy in 2021-22 among patients with peripheral artery disease. Vasc Med. 2023 06; 28(3):233-235.
    View in: PubMed
    Score: 0.511
  15. Hess CN, Bonaca MP. Guideline-Directed Medical Therapy in?PAD: Time to Step on the Gas. JACC Cardiovasc Interv. 2023 02 13; 16(3):344-346.
    View in: PubMed
    Score: 0.510
  16. Bonaca MP, Hogan SE. Tradeoffs in Approach to PAD?Revascularization: Shared Decision Making in the Spotlight. J Am Coll Cardiol. 2023 01 31; 81(4):371-373.
    View in: PubMed
    Score: 0.509
  17. Govsyeyev N, Nehler M, Conte MS, Debus S, Chung J, Dorigo W, Gudz I, Krievins D, Mills J, Moll F, Norgren L, Piffaretti G, Powell R, Szalay D, Sillesen H, Wohlauer M, Szarek M, Bauersachs RM, Anand SS, Patel MR, Capell WH, Jaeger N, Hess CN, Muehlhofer E, Haskell LP, Berkowitz SD, Bonaca MP. Rivaroxaban in patients with symptomatic peripheral artery disease after lower extremity bypass surgery with venous and prosthetic conduits. J Vasc Surg. 2023 04; 77(4):1107-1118.e2.
    View in: PubMed
    Score: 0.503
  18. Bonaca MP, Szarek M, Debus ES, Nehler MR, Patel MR, Anand SS, Muehlhofer E, Berkowitz SD, Haskell LP, Bauersachs RM. Efficacy and safety of rivaroxaban versus placebo after lower extremity bypass surgery: A post hoc analysis of a "CASPAR like" outcome from VOYAGER PAD. Clin Cardiol. 2022 Dec; 45(12):1143-1146.
    View in: PubMed
    Score: 0.498
  19. Bonaca MP, Hess C, Beckman JA. Telmisartan and Walking Performance in Peripheral Artery Disease. JAMA. 2022 10 04; 328(13):1302-1303.
    View in: PubMed
    Score: 0.497
  20. Bonaca MP, Antman EM, Cunningham JW, Wiviott SD, Murphy SA, Halperin JL, Weitz JI, Grosso MA, Lanz HJ, Braunwald E, Giugliano RP, Ruff CT. Ischaemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full- and half-dose edoxaban vs. warfarin: insights from ENGAGE AF-TIMI 48. Eur Heart J Cardiovasc Pharmacother. 2022 Sep 29; 8(7):695-706.
    View in: PubMed
    Score: 0.497
  21. Hess CN, Bonaca MP. Risk of remnants and remnant risk in peripheral artery disease. Eur Heart J. 2022 09 07; 43(34):3270-3272.
    View in: PubMed
    Score: 0.495
  22. Hess CN, Szarek M, Anand SS, Bauersachs RM, Patel MR, Debus ES, Nehler MR, Capell WH, Beckman JA, Piazza G, Henkin S, Bura-Rivi?re A, Lawall H, Roztocil K, Hsia J, Muehlhofer E, Berkowitz SD, Haskell LP, Bonaca MP. Rivaroxaban and Risk of Venous Thromboembolism in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity Revascularization. JAMA Netw Open. 2022 06 01; 5(6):e2215580.
    View in: PubMed
    Score: 0.486
  23. Szarek M, Hess C, Patel MR, Jones WS, Berger JS, Baumgartner I, Katona B, Mahaffey KW, Norgren L, Blomster J, Rockhold FW, Hsia J, Fowkes FGR, Bonaca MP. Total Cardiovascular and Limb Events and the Impact of Polyvascular Disease in Chronic Symptomatic Peripheral Artery Disease. J Am Heart Assoc. 2022 06 07; 11(11):e025504.
    View in: PubMed
    Score: 0.485
  24. Anand SS, Hiatt W, Dyal L, Bauersachs R, Berkowitz SD, Branch KRH, Debus S, Fox KAA, Liang Y, Muehlhofer E, Nehler M, Haskell LP, Patel M, Szarek M, Yusuf S, Eikelboom J, Bonaca MP. Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials. Eur J Prev Cardiol. 2022 05 05; 29(5):e181-e189.
    View in: PubMed
    Score: 0.483
  25. Behan SA, Mulder H, Rockhold FW, Gutierrez JA, Baumgartner I, Katona BG, Mahaffey KW, Norgren L, Jones S, Bonaca MP. Impact of Polyvascular Disease and Diabetes on?Limb and Cardiovascular Risk in Peripheral Artery Disease. J Am Coll Cardiol. 2022 05 03; 79(17):1781-1783.
    View in: PubMed
    Score: 0.483
  26. Hogan SE, Nehler MR, Anand S, Patel MR, Debus S, Jackson MT, Buchanan C, King RW, Hess C, Muehlhofer E, Haskell LP, Bauersachs RM, Berkowitz SD, Hsia J, Bonaca MP. Improvement in walking impairment following surgical and endovascular revascularization: Insights from VOYAGER PAD. Vasc Med. 2022 08; 27(4):343-349.
    View in: PubMed
    Score: 0.482
  27. Verma S, Al-Omran M, Leiter LA, Mazer CD, Rasmussen S, Saevereid HA, Sejersten Ripa M, Bonaca MP. Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease. Diabetes Obes Metab. 2022 07; 24(7):1288-1299.
    View in: PubMed
    Score: 0.481
  28. Berkowitz SD, Bauersachs RM, Szarek M, Nehler MR, Debus ES, Patel MR, Anand SS, Capell WH, Hess CN, Hsia J, Leeper NJ, Brasil D, M?ty?s L, Diaz R, Brodmann M, Muehlhofer E, Haskell LP, Bonaca MP. Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy alone. J Thromb Haemost. 2022 05; 20(5):1193-1205.
    View in: PubMed
    Score: 0.478
  29. Morrison JT, Govsyeyev N, Hess CN, Bonaca MP. Vorapaxar for Prevention of Major Adverse Cardiovascular and Limb Events in Peripheral Artery Disease. J Cardiovasc Pharmacol Ther. 2022 Jan-Dec; 27:10742484211056115.
    View in: PubMed
    Score: 0.472
  30. Hess CN, Patel MR, Bauersachs RM, Anand SS, Debus ES, Nehler MR, Fanelli F, Yeh RW, Secemsky EA, Beckman JA, Mauri L, Govsyeyev N, Capell WH, Brackin T, Berkowitz SD, Muehlhofer E, Haskell LP, Hiatt WR, Bonaca MP. Safety and Effectiveness of Paclitaxel Drug-Coated Devices in Peripheral Artery?Revascularization: Insights From VOYAGER PAD. J Am Coll Cardiol. 2021 11 02; 78(18):1768-1778.
    View in: PubMed
    Score: 0.466
  31. Krantz MJ, Debus SE, Hsia J, Patel MR, Anand SS, Nehler MR, Hess CN, Capell WH, Bracken T, Szarek M, M?ty?s L, Krievins DK, Nault P, Stefanov S, Haskell LP, Berkowitz SD, Muehlhofer E, Hiatt WR, Bauersachs RM, Bonaca MP. Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trial. Eur Heart J. 2021 10 14; 42(39):4040-4048.
    View in: PubMed
    Score: 0.465
  32. Gilchrist IC, Morrow DA, Creager MA, Olin JW, Scirica BM, Goodrich EL, Bonaca MP. Efficacy and Safety of Vorapaxar by Intensity of Background Lipid-Lowering Therapy in Patients With Peripheral Artery Disease: Insights From the TRA2P-TIMI 50 Trial. J Am Heart Assoc. 2021 10 19; 10(20):e021412.
    View in: PubMed
    Score: 0.464
  33. Govsyeyev N, Nehler MR, Low Wang CC, Kavanagh S, Hiatt WR, Long C, Jones WS, Fowkes FGR, Berger JS, Baumgartner I, Patel MR, Goodney PP, Beckman JA, Katona BG, Mahaffey KW, Blomster J, Norgren L, Bonaca MP. Etiology and outcomes of amputation in patients with peripheral artery disease in the EUCLID trial. J Vasc Surg. 2022 02; 75(2):660-670.e3.
    View in: PubMed
    Score: 0.463
  34. Hsia J, Szarek M, Anand S, Patel MR, Debus S, Berkowitz SD, Muehlhofer E, Haskell LP, Bauersachs RM, Bonaca MP. Rivaroxaban in Patients With Recent Peripheral Artery Revascularization and Renal Impairment: The VOYAGER PAD Trial. J Am Coll Cardiol. 2021 08 17; 78(7):757-759.
    View in: PubMed
    Score: 0.460
  35. Debus ES, Nehler MR, Govsyeyev N, Bauersachs RM, Anand SS, Patel MR, Fanelli F, Capell WH, Brackin T, Hinterreiter F, Krievins D, Nault P, Piffaretti G, Svetlikov A, Jaeger N, Hess CN, Sillesen HH, Conte M, Mills J, Muehlhofer E, Haskell LP, Berkowitz SD, Hiatt WR, Bonaca MP. Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Trial. Circulation. 2021 10 05; 144(14):1104-1116.
    View in: PubMed
    Score: 0.459
  36. Hess CN, Cannon CP, Beckman JA, Goodney PP, Patel MR, Hiatt WR, Mues KE, Orroth KK, Shannon E, Bonaca MP. Effectiveness of Blood Lipid Management in Patients With Peripheral Artery Disease. J Am Coll Cardiol. 2021 06 22; 77(24):3016-3027.
    View in: PubMed
    Score: 0.455
  37. Bonaca MP, Hamburg NM, Creager MA. Contemporary Medical Management of Peripheral Artery Disease. Circ Res. 2021 06 11; 128(12):1868-1884.
    View in: PubMed
    Score: 0.454
  38. Hess CN, Fu JW, Gundrum J, Allen LaPointe NM, Wang TY, Rogers RK, Hiatt WR, Bonaca MP. Diabetes Mellitus and Risk Stratification After Peripheral Artery Revascularization. J Am Coll Cardiol. 2021 06 08; 77(22):2867-2869.
    View in: PubMed
    Score: 0.454
  39. Hsia J, Kavanagh ST, Hopley CW, Baumgartner I, Berger JS, Fowkes GR, Jones WS, Mahaffey KW, Norgren L, Patel MR, Rockhold F, Blomster J, Katona BG, Hiatt WR, Bonaca MP. Impact of chronic kidney disease on hemoglobin among patients with peripheral artery disease treated with P2Y12 inhibitors: Insights from the EUCLID trial. Vasc Med. 2021 12; 26(6):608-612.
    View in: PubMed
    Score: 0.453
  40. Desai U, Kharat A, Hess CN, Milentijevic D, Lalibert? F, Zuckerman P, Benson J, Lefebvre P, Hiatt WR, Bonaca MP. Incidence of Major Atherothrombotic Vascular Events among Patients with Peripheral Artery Disease after Revascularization. Ann Vasc Surg. 2021 Aug; 75:217-226.
    View in: PubMed
    Score: 0.448
  41. Desai U, Kharat A, Hess CN, Milentijevic D, Lalibert? F, Zuckerman P, Benson J, Lefebvre P, Hiatt WR, Bonaca MP. Healthcare resource utilization and costs of major atherothrombotic vascular events among patients with peripheral artery disease after revascularization. J Med Econ. 2021 Jan-Dec; 24(1):402-409.
    View in: PubMed
    Score: 0.440
  42. Bonaca MP, Bauersachs RM, Hiatt WR. Rivaroxaban in Peripheral Artery Disease after Revascularization. Reply. N Engl J Med. 2020 11 19; 383(21):2090-2091.
    View in: PubMed
    Score: 0.437
  43. Hess CN, Bonaca MP. Contemporary Review of Antithrombotic Therapy in Peripheral Artery Disease. Circ Cardiovasc Interv. 2020 10; 13(10):e009584.
    View in: PubMed
    Score: 0.433
  44. Bonaca MP, Wiviott SD, Zelniker TA, Mosenzon O, Bhatt DL, Leiter LA, McGuire DK, Goodrich EL, De Mendonca Furtado RH, Wilding JPH, Cahn A, Gause-Nilsson IAM, Johanson P, Fredriksson M, Johansson PA, Langkilde AM, Raz I, Sabatine MS. Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58. Circulation. 2020 08 25; 142(8):734-747.
    View in: PubMed
    Score: 0.428
  45. Bonaca MP, Hess CN. ASCVD Risk and Statin Use in PAD: Implementing a New Approach to an Old Problem. J Am Coll Cardiol. 2020 07 21; 76(3):265-267.
    View in: PubMed
    Score: 0.427
  46. Bonaca MP, Bauersachs RM, Anand SS, Debus ES, Nehler MR, Patel MR, Fanelli F, Capell WH, Diao L, Jaeger N, Hess CN, Pap AF, Kittelson JM, Gudz I, M?ty?s L, Krievins DK, Diaz R, Brodmann M, Muehlhofer E, Haskell LP, Berkowitz SD, Hiatt WR. Rivaroxaban in Peripheral Artery Disease after Revascularization. N Engl J Med. 2020 05 21; 382(21):1994-2004.
    View in: PubMed
    Score: 0.418
  47. Bonaca MP, Hess CN, Hiatt WR. The Pathobiology of Acute Limb Ischemic?Events and Stent Failure in Peripheral Artery Disease: A Step in the Right Direction. JACC Cardiovasc Interv. 2020 02 24; 13(4):428-430.
    View in: PubMed
    Score: 0.415
  48. Qamar A, Morrow DA, Creager MA, Scirica BM, Olin JW, Beckman JA, Murphy SA, Bonaca MP. Effect of vorapaxar on cardiovascular and limb outcomes in patients with peripheral artery disease with and without coronary artery disease: Analysis from the TRA 2?P-TIMI 50 trial. Vasc Med. 2020 04; 25(2):124-132.
    View in: PubMed
    Score: 0.413
  49. Govsyeyev N, Nehler MR, Hiatt WR, Bonaca MP. Tackling Elevated Risk in PAD: Focus on Antithrombotic and Lipid Therapy for PAD. Curr Cardiol Rep. 2020 Jan 29; 22(3):13.
    View in: PubMed
    Score: 0.413
  50. Patel SM, Morrow DA, Kidd SK, Goodrich EL, Scirica BM, Bonaca MP. Vorapaxar for secondary prevention in the elderly with peripheral artery disease: Insights from the TRA 2?P-TIMI 50 trial. Vasc Med. 2019 04; 24(2):159-161.
    View in: PubMed
    Score: 0.389
  51. Creager MA, Bonaca MP. Pathology of Arterial Disease in Limb?Loss: The Clot Thickens. J Am Coll Cardiol. 2018 10 30; 72(18):2164-2165.
    View in: PubMed
    Score: 0.379
  52. Bonaca MP. Polyvascular disease and risk: When two is not better than one. Vasc Med. 2018 12; 23(6):531-533.
    View in: PubMed
    Score: 0.376
  53. Bonaca MP, Sabatine MS. Response by Bonaca and Sabatine to Letters Regarding Article, "Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)". Circulation. 2018 07 10; 138(2):222-223.
    View in: PubMed
    Score: 0.371
  54. Bonaca MP, Creager MA. Antithrombotic Therapy and Major?Adverse Limb Events in Peripheral?Artery?Disease: A Step Forward. J Am Coll Cardiol. 2018 05 22; 71(20):2316-2318.
    View in: PubMed
    Score: 0.367
  55. Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E, Kuder J, Murphy SA, Jukema JW, Lewis BS, Tokgozoglu L, Somaratne R, Sever PS, Pedersen TR, Sabatine MS. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). Circulation. 2018 01 23; 137(4):338-350.
    View in: PubMed
    Score: 0.354
  56. Bonaca MP, Creager MA, Olin J, Scirica BM, Gilchrist IC, Murphy SA, Goodrich EL, Braunwald E, Morrow DA. Peripheral Revascularization in Patients With?Peripheral Artery Disease With?Vorapaxar: Insights From the TRA 2?P-TIMI 50 Trial. JACC Cardiovasc Interv. 2016 10 24; 9(20):2157-2164.
    View in: PubMed
    Score: 0.329
  57. Bonaca MP. Antithrombotic Therapy in Patients With Peripheral Artery Disease. JAMA Cardiol. 2016 10 01; 1(7):803-804.
    View in: PubMed
    Score: 0.328
  58. Bonaca MP, Bhatt DL, Storey RF, Steg PG, Cohen M, Kuder J, Goodrich E, Nicolau JC, Parkhomenko A, L?pez-Send?n J, Dellborg M, Dalby A, ?pinar J, Aylward P, Corbal?n R, Abola MTB, Jensen EC, Held P, Braunwald E, Sabatine MS. Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. J Am Coll Cardiol. 2016 Jun 14; 67(23):2719-2728.
    View in: PubMed
    Score: 0.317
  59. Bonaca MP, Gutierrez JA, Creager MA, Scirica BM, Olin J, Murphy SA, Braunwald E, Morrow DA. Acute Limb Ischemia and Outcomes With Vorapaxar in Patients With Peripheral Artery Disease: Results From the Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Patients With Atherosclerosis-Thrombolysis in Myocardial Infarction 50 (TRA2?P-TIMI 50). Circulation. 2016 Mar 08; 133(10):997-1005.
    View in: PubMed
    Score: 0.313
  60. Bonaca MP, Creager MA. Pharmacological treatment and current management of peripheral artery disease. Circ Res. 2015 Apr 24; 116(9):1579-98.
    View in: PubMed
    Score: 0.297
  61. Bonaca MP, Scirica BM, Creager MA, Olin J, Bounameaux H, Dellborg M, Lamp JM, Murphy SA, Braunwald E, Morrow DA. Vorapaxar in patients with peripheral artery disease: results from TRA2{degrees}P-TIMI 50. Circulation. 2013 Apr 09; 127(14):1522-9, 1529e1-6.
    View in: PubMed
    Score: 0.256
  62. Divakaran S, Harms HJ, Robertson M, Merugumala SK, Park MA, Kijewski MF, Martell LB, Morgan V, Barrett L, Perillo A, Yang D, Jarolim P, Feinberg MW, Gerhard-Herman MD, Belkin M, Lin AP, Creager MA, Bonaca MP, Di Carli MF. Post-walking exercise skeletal muscle perfusion and energetics in patients with symptomatic lower extremity peripheral artery disease. J Nucl Cardiol. 2025 Apr; 46:102143.
    View in: PubMed
    Score: 0.146
  63. Fowler X, Mehta K, Eid M, Gladders B, Kearing S, Moore KO, Creager MA, Austin AM, Feinberg MW, Bonaca MP, Greenland P, McDermott MM, Goodney PP. Trends in patient characteristics and mortality among Medicare patients diagnosed with peripheral artery disease. Vasc Med. 2024 12; 29(6):653-663.
    View in: PubMed
    Score: 0.142
  64. Ponukumati AS, Krafcik BM, Newton L, Baribeau V, Mao J, Zhou W, Goodney EJ, Fowler XP, Eid MA, Moore KO, Armstrong DG, Feinberg MW, Bonaca MP, Creager MA, Goodney PP. Association between tissue loss type and amputation risk among Medicare patients with concomitant diabetes and peripheral arterial disease. J Vasc Surg. 2024 Nov; 80(5):1543-1552.e12.
    View in: PubMed
    Score: 0.140
  65. Bonaca MP, Bhatt DL, Simon T, Fox KM, Mehta S, Harrington RA, Leiter LA, Capell WH, Held C, Himmelmann A, Ridderstr?le W, Chen J, Lee JJ, Song Y, Andersson M, Prats J, Kosiborod M, McGuire DK, Steg PG. Limb Outcomes With Ticagrelor Plus Aspirin in Patients With Diabetes Mellitus and Atherosclerosis. J Am Coll Cardiol. 2024 Apr 30; 83(17):1627-1636.
    View in: PubMed
    Score: 0.139
  66. Hogan SE, Debus ES, Nehler MR, Patel MR, Anand SS, Muehlhofer E, Haskell LP, Berkowitz SD, Bauersachs RM, Bonaca MP. Unplanned Index Limb Revascularization With Rivaroxaban Versus Placebo in Patients With Critical Limb-Threatening Ischemia After Endovascular and Surgical Treatment: Insights From VOYAGER PAD. Circulation. 2024 02 20; 149(8):635-637.
    View in: PubMed
    Score: 0.137
  67. Farber A, Menard MT, Bonaca MP, Bradbury A, Conte MS, Debus ES, Eldrup N, Goodney P, Gupta PC, Hinchliffe RJ, Houlind KC, Kolh P, Kum SWC, Nordanstig J, Parikh SA, Patel MR, Patrone L, Sillesen H, Strong MB, Varcoe RL, Vega de Ceniga M, Venermo MA, Rosenfield K. BEST-CLI International Collaborative: planning a better future for patients with chronic limb-threatening ischaemia globally. Br J Surg. 2024 01 31; 111(2).
    View in: PubMed
    Score: 0.136
  68. Varcoe RL, DeRubertis BG, Kolluri R, Krishnan P, Metzger DC, Bonaca MP, Shishehbor MH, Holden AH, Bajakian DR, Garcia LA, Kum SWC, Rundback J, Armstrong E, Lee JK, Khatib Y, Weinberg I, Garcia-Garcia HM, Ruster K, Teraphongphom NT, Zheng Y, Wang J, Jones-McMeans JM, Parikh SA. Drug-Eluting Resorbable Scaffold versus Angioplasty for Infrapopliteal Artery Disease. N Engl J Med. 2024 Jan 04; 390(1):9-19.
    View in: PubMed
    Score: 0.134
  69. Rymer J, Anand SS, Sebastian Debus E, Haskell LP, Hess CN, Jones WS, Muehlhofer E, Berkowitz SD, Bauersachs RM, Bonaca MP, Patel MR. Rivaroxaban Plus Aspirin Versus Aspirin Alone After Endovascular Revascularization for Symptomatic PAD: Insights From VOYAGER PAD. Circulation. 2023 12 12; 148(24):1919-1928.
    View in: PubMed
    Score: 0.134
  70. Fowler XP, Eid MA, Barnes JA, Gladders B, Austin AM, Goodney EJ, Moore KO, Kearing S, Feinberg MW, Bonaca MP, Creager MA, Goodney PP. Trends of Concomitant Diabetes and Peripheral Artery Disease and Lower Extremity Amputation in US Medicare Patients, 2007 to 2019. Circ Cardiovasc Qual Outcomes. 2023 06; 16(6):e009531.
    View in: PubMed
    Score: 0.131
  71. Verma S, Dhingra NK, Bonaca MP, Butler J, Anker SD, Ferreira JP, Filippatos G, Januzzi JL, Lam CSP, Sattar N, Iwata T, Nordaby M, Brueckmann M, Pocock SJ, Packer M. Presence of Peripheral Artery Disease Is Associated With Increased Risk of Heart Failure Events: Insights From EMPEROR-Pooled. Arterioscler Thromb Vasc Biol. 2023 07; 43(7):1334-1337.
    View in: PubMed
    Score: 0.130
  72. Cheng HS, Zhuang R, P?rez-Cremades D, Chen J, Jamaiyar A, Wu W, Sausen G, Tzani A, Plutzky J, Henao-Mejia J, Goodney PP, Creager MA, Sabatine MS, Bonaca MP, Feinberg MW. A miRNA/CXCR4 signaling axis impairs monopoiesis and angiogenesis in diabetic critical limb ischemia. JCI Insight. 2023 04 10; 8(7).
    View in: PubMed
    Score: 0.129
  73. Austin AM, Ramkumar N, Gladders B, Barnes JA, Eid MA, Moore KO, Feinberg MW, Creager MA, Bonaca M, Goodney PP. Using a cohort study of diabetes and peripheral artery disease to compare logistic regression and machine learning via random forest modeling. BMC Med Res Methodol. 2022 11 23; 22(1):300.
    View in: PubMed
    Score: 0.125
  74. Aday AW, Duncan MS, Patterson OV, DuVall SL, Alba PR, Alcorn CW, Tindle HA, Creager MA, Bonaca MP, Damrauer SM, Wells QS, Behroozian A, Beckman JA, Freiberg MS. Association of Sex and Race With Incident Peripheral Artery Disease Among Veterans With Normal Ankle-Brachial Indices. JAMA Netw Open. 2022 11 01; 5(11):e2240188.
    View in: PubMed
    Score: 0.125
  75. Hess CN, Baumgartner I, Anand SS, Nehler MR, Patel MR, Debus ES, Szarek M, Capell W, Muehlhofer E, Berkowitz SD, Haskell LP, Bauersachs RM, Bonaca MP, Hsia J. Sex-Based Differences in Outcomes Following Peripheral Artery Revascularization: Insights From VOYAGER PAD. J Am Heart Assoc. 2022 06 21; 11(12):e024655.
    View in: PubMed
    Score: 0.122
  76. Secemsky EA, Barrette E, Bockstedt L, Bonaca MP, Hess CN, Hanson T, Monteiro J, Manda B, Yeh RW. Long-term safety of drug-coated devices for peripheral revascularisation. EuroIntervention. 2021 Sep 20; 17(7):590-598.
    View in: PubMed
    Score: 0.116
  77. Divakaran S, Carroll BJ, Chen S, Shen C, Bonaca MP, Secemsky EA. Supervised Exercise Therapy for Symptomatic Peripheral Artery Disease Among Medicare Beneficiaries Between 2017 and 2018: Participation Rates and Outcomes. Circ Cardiovasc Qual Outcomes. 2021 08; 14(8):e007953.
    View in: PubMed
    Score: 0.114
  78. Hiatt WR, Hess CN, Bonaca MP, Kavanagh S, Patel MR, Baumgartner I, Berger JS, Blomster JI, Jones WS, Katona BG, Mahaffey KW, Norgren L, Rockhold FW, Fowkes FGR. Ankle-Brachial Index for Risk Stratification in Patients With Symptomatic Peripheral Artery Disease With and Without Prior Lower Extremity Revascularization: Observations From the EUCLID Trial. Circ Cardiovasc Interv. 2021 07; 14(7):e009871.
    View in: PubMed
    Score: 0.114
  79. Bauersachs RM, Szarek M, Brodmann M, Gudz I, Debus ES, Nehler MR, Anand SS, Patel MR, Hess CN, Capell WH, Rogers K, Muehlhofer E, Haskell LP, Berkowitz SD, Hiatt WR, Bonaca MP. Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD?Trial. J Am Coll Cardiol. 2021 07 27; 78(4):317-326.
    View in: PubMed
    Score: 0.113
  80. Hiatt WR, Bonaca MP, Patel MR, Nehler MR, Debus ES, Anand SS, Capell WH, Brackin T, Jaeger N, Hess CN, Pap AF, Berkowitz SD, Muehlhofer E, Haskell L, Brasil D, Madaric J, Sillesen H, Szalay D, Bauersachs R. Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization: Impact of Concomitant Clopidogrel on Efficacy and Safety. Circulation. 2020 12 08; 142(23):2219-2230.
    View in: PubMed
    Score: 0.109
  81. De Luca L, Bonaca MP, Magnani G. Antithrombotic strategies for patients with coronary and lower extremity peripheral artery diseases: a narrative review. Expert Rev Cardiovasc Ther. 2020 Dec; 18(12):881-889.
    View in: PubMed
    Score: 0.108
  82. Barnett JV, Beckman JA, Bonaca MP, Carnethon MR, Cassis LA, Creager MA, Daugherty A, Feinberg MW, Freiberg MS, Goodney PP, Greenland P, Leeuwenburgh C, LeMaire SA, McDermott MM, Sabatine MS, Shen YH, Wasserman DH, Webb NR, Wells QS. American Heart Association Vascular Disease Strategically Focused Research Network. Arterioscler Thromb Vasc Biol. 2020 03; 40(3):e47-e54.
    View in: PubMed
    Score: 0.103
  83. Beckman JA, Duncan MS, Damrauer SM, Wells QS, Barnett JV, Wasserman DH, Bedimo RJ, Butt AA, Marconi VC, Sico JJ, Tindle HA, Bonaca MP, Aday AW, Freiberg MS. Microvascular Disease, Peripheral Artery Disease, and Amputation. Circulation. 2019 08 06; 140(6):449-458.
    View in: PubMed
    Score: 0.099
  84. Capell WH, Bonaca MP, Nehler MR, Chen E, Kittelson JM, Anand SS, Berkowitz SD, Debus ES, Fanelli F, Haskell L, Patel MR, Bauersachs R, Hiatt WR. Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD). Am Heart J. 2018 05; 199:83-91.
    View in: PubMed
    Score: 0.090
  85. Pandey A, Banerjee S, Ngo C, Mody P, Marso SP, Brilakis ES, Armstrong EJ, Giri J, Bonaca MP, Pradhan A, Bavry AA, Kumbhani DJ. Comparative Efficacy of Endovascular Revascularization Versus Supervised Exercise Training in Patients With Intermittent Claudication: Meta-Analysis of Randomized Controlled Trials. JACC Cardiovasc Interv. 2017 04 10; 10(7):712-724.
    View in: PubMed
    Score: 0.085
  86. Kidd SK, Bonaca MP, Braunwald E, De Ferrari GM, Lewis BS, Merlini PA, Murphy SA, Scirica BM, White HD, Morrow DA. Universal Classification System Type of Incident Myocardial Infarction in Patients With Stable Atherosclerosis: Observations From Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2?P)-TIMI 50. J Am Heart Assoc. 2016 07 18; 5(7).
    View in: PubMed
    Score: 0.081
  87. Magnani G, Bonaca MP, Braunwald E, Dalby AJ, Fox KA, Murphy SA, Nicolau JC, Oude Ophuis T, Scirica BM, Spinar J, Theroux P, Morrow DA. Efficacy and safety of vorapaxar as approved for clinical use in the United States. J Am Heart Assoc. 2015 Mar 19; 4(3):e001505.
    View in: PubMed
    Score: 0.074
  88. Mok Y, Ballew SH, Bash LD, Bhatt DL, Boden WE, Bonaca MP, Carrero JJ, Coresh J, D'Agostino RB, Elley CR, Fowkes FGR, Jee SH, Kovesdy CP, Mahaffey KW, Nadkarni G, Peterson ED, Sang Y, Matsushita K. International Validation of the Thrombolysis in Myocardial Infarction (TIMI) Risk Score for Secondary Prevention in Post-MI Patients: A Collaborative Analysis of the Chronic Kidney Disease Prognosis Consortium and the Risk Validation Scientific Committee. J Am Heart Assoc. 2018 07 07; 7(14).
    View in: PubMed
    Score: 0.023
  89. Morrow DA, Alberts MJ, Mohr JP, Ameriso SF, Bonaca MP, Goto S, Hankey GJ, Murphy SA, Scirica BM, Braunwald E. Efficacy and safety of vorapaxar in patients with prior ischemic stroke. Stroke. 2013 Mar; 44(3):691-8.
    View in: PubMed
    Score: 0.016
  90. Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, Fox KA, Lipka LJ, Liu X, Nicolau JC, Ophuis AJ, Paolasso E, Scirica BM, Spinar J, Theroux P, Wiviott SD, Strony J, Murphy SA. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012 Apr 12; 366(15):1404-13.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)